The endocannabinoid system and its therapeutic exploitation

Nature Reviews Drug Discovery

Volumn 3, Issue 9, 2004, Pages 771-784

  Di Marzo, Vincenzo ^a   Bifulco, Maurizio ^b   De Petrocellis, Luciano ^a  

^a CNR   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ACYLGLYCEROL LIPASE; ANANDAMIDE; CANNABICHROMENE; CANNABIDIOL; CANNABIDIOLIC ACID; CANNABIGEROL; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; CANNABIS DERIVATIVE; CP 55245; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; HU 245; ICOSANOID; LIPOPROTEIN LIPASE; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; PHOSPHOLIPASE C; PHOSPHOLIPASE D; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING AFFINITY; BIOSYNTHESIS; CARCINOGENESIS; CELLULAR DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL DISEASE; HUMAN; MEMBRANE TRANSPORT; MOLECULAR MECHANICS; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; VOMITING;

ANIMALS; CANNABINOIDS; CANNABIS; CLINICAL TRIALS; DRUG DESIGN; ENDOCANNABINOIDS; ENZYMES; HUMANS; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION;

EID: 4544275181     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1495     Document Type: Review

References (163)

1. Adams, I. B. & Martin, B. R. Cannabis: pharmacology and toxicology in animals and humans. Addiction 91, 1585-1614 (1996).
2. Mechoulam, R. in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1-19 (CRC Press Roca Renton, 1986).
3. Williamson, E. M. & Evans, F. J. Cannabinoids in clinical practice. Drugs 60 1303-1314 (2000).
4. Gaoni, Y. & Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646-1647 (1964).
5. Walsh, D., Nelson, K. A. & Mahmoud, F. A. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11, 137-143 (2003).
6. Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S. & Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605-613 (1988).
7. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564 (1990).
8. Mechoulam, R. & Hanus, L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem. Phys. Lipids 121, 35-43 (2002).
9. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (1993).
10. Di Marzo, V. & Fontana, A. Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostaglandins Leukot. Essent. Fatty Acids 53, 1-11 (1995).
11. Devane, W. A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949 (1992).
12. Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochem. Pharmacol. 50, 83-90 (1995).
13. Sugiura, T. et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Commun. 215, 89-97 (1995).
14. 2 receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids 66, 161-171 (2002).
15. Di Marzo, V., De Petrocellis, L., Fezza, F., Ligresti, A. & Bisogno, T. Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids 66, 377-391 (2002).
16. Piomelli, D. The molecular logic of endocannabinoid signalling. Nature Rev. Neurosci. 4, 873-884 (2003).
17. De Petrocellis, L., Cascio, M. G. & Di Marzo, V. The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 141, 765-774 (2004).
18. 2 receptors. Pharmacol. Ther. 74, 129-180 (1997).
19. Howlett, A. C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35, 607-634 (1995).
20. Di Marzo, V., Melck, D., Bisogno, T. & De Petrocellis, L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21, 521-528 (1998).
21. Schlicker, E. & Kathmann, M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22, 565-572 (2001).
22. Wilson, R. I. & Nicoll, R. A. Endocannabinoid signaling in the brain. Science 296, 678-682 (2002).
23. Freund, T. F., Katona, I. & Piomelli, D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83, 1017-1066 (2003).
24. Parolaro, D. & Rubino, T. Is cannabinoid transmission involved in rewarding properties of drugs of abuse? Br. J. Pharmacol. 136, 1083-1084 (2002).
25. Gerdeman, G. L., Partridge, J. G., Lupica, C. R. & Lovinger, D. M. It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci. 26, 184-192 (2003).
26. Iversen, L. & Chapman, V. Cannabinoids: a real prospect for pain relief? Curr. Opin. Pharmacol. 2, 50-55 (2002).
27. Randall, M. D., Harris, D., Kendall, D. A. & Ralevic, V. Cardiovascular effects of cannabinoids. Pharmacol. Ther. 95, 191-202 (2002).
28. Di Carlo, G. & Izzo, A. A. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert. Opin. Investig. Drugs 12, 39-49 (2003).
29. Schmid, K., Niederhoffer, N. & Szabo, B. Analysis of the respiratory effects of cannabinoids in rats. Naunyn Schmiedebergs Arch. Pharmacol. 368, 301-308 (2003).
30. Wenger, T. & Moldrich, G. The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot. Essent. Fatty Acids 66, 301-307 (2002).
31. Park, B., McPartland, J. M. & Glass, M. Cannabis, cannabinoids and reproduction. Prostaglandins Leukot. Essent. Fatty Acids 70, 189-197 (2004).
32. Klein, T. W. et al. The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 486-496 (2003).
33. Guzman, M., Sanchez, C. & Galve-Roperh, I. Cannabinoids and cell fate. Pharmacol. Ther. 95, 175-184 (2002).
34. Di Marzo, V., Bisogno, T., De Petrocellis, L., Berger, A. & Mechoulam, R. in Biology of Marijuana (ed. Onaivi, E.) 125-173 (Harwood Academic, Reading, 2002).
35. 1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88 (2003).
36. Kirkham, T. C., Williams, C. M., Fezza, F. & Di Marzo, V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 136, 550-557 (2002).
37. Marsicano, G. et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530-534 (2002).
38. Walker, J. M., Huang, S. M., Strangman, N. M., Tsou, K. & Sanudo-Pena, M. C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl Acad. Sci. USA 96, 12198-12203 (1999).
39. Di Marzo, V. et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822-825 (2001).
40. Cota, D. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423-431 (2003).
41. Schabitz, W. R. et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 33, 2112-2114 (2002).
42. 1 cannabinoid receptor knock-out mice. J. Neurosci. 22, 9771-9775 (2002).
43. Panikashvili, D. et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527-531 (2001).
44. Di Marzo, V., Hill, M. P., Bisogno, T., Crossman, A. R. & Brotchie, J. M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14, 1432-1438 (2000).
45. Maccarrone, M. et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. 85, 1018-1025 (2003).
46. Baker, D. et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15, 300-302 (2001).
47. Baker, D. et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404, 84-87 (2000).
48. 1 receptor blockade. Eur. J. Pharmacol. 477, 219-225 (2003).
49. 1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol. 169, 400-406 (2001).
50. 1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41, 195-202 (2001).
51. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23, 11136-11141 (2003).
52. Lastres-Becker, I. et al. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport 12, 2125-2129 (2001).
53. Denovan-Wright, E. M. & Robertson, H. A. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98, 705-713 (2000).
54. Glass, M., Faull, R. L. & Dragunow, M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56, 523-527 (1993).
55. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63, 908-914 (2003).
56. 1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 234, R345-R353 (2003).
57. 1 cannabinoid receptor knockout in mice leads to leannes, resistence to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28, 640-648 (2004).
58. 1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518-521 (1997).
59. Varga, K., Wagner, J. A., Bridgen, D. T. & Kunos, G. Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12, 1035-1044 (1998).
60. 1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nature Med. 7, 827-832 (2001).
61. Wagner, J. A. et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J. Am. Coll. Cardiol. 38, 2048-2054 (2001).
62. 1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol. 134, 563-570 (2001).
63. Izzo, A. A. et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125, 765-774 (2003).
64. Mascolo, N. et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J. 16, 1973-1975 (2002).
65. Massa, F. et al. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113, 1202-1209 (2004).
66. Wang, H. et al. Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation. Proc. Natl Acad. Sci. USA 100, 14914-14919 (2003).
67. Maccarrone, M. et al. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 355, 1326-1329 (2000).
68. Maccarrone, M. et al. Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol. Hum. Reprod. 8, 188-195 (2002).
69. Ligresti, A. et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125, 677-687 (2003).
70. Schmid, P. C., Wold, L. E., Krebsbach, R. J., Berdyshev, E. V. & Schmid, H. H. Anandamide and other N-acylethanolamines in human tumors. Lipids 37, 907-912 (2002).
71. Sanchez, C. et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61, 5784-5789 (2001).
72. De Petrocellis, L. et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl Acad. Sci. USA 95, 8375-8380 (1998).
73. Galve-Roperh, I. et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Med. 6, 313-319 (2000).
74. Bifulco, M. et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 15, 2745-2747 (2001).
75. Casanova, M. L. et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111, 43-50 (2003).
76. 1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 17, 1771-1773 (2003).
77. Bifulco, M. et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASLB J. 2 August 2004 (doi:10-1096/fj.04-1754fje).
78. 2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104, 526-534 (2004).
79. Cravatt, B. F. & Lichtman, A. H. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr. Opin. Chem. Biol. 7, 469-475 (2003).
80. Di Marzo, V. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691 (1994).
81. Di Marzo, V., De Petrocellis, L., Sepe, N. & Buono, A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 316, 977-984 (1996).
82. Bisogno, T. et al. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. 322, 671-677 (1997).
83. Stella, N., Schweitzer, P. & Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778 (1997).
84. Schmid, P. C., Reddy, P. V., Natarajan, V. & Schmid, H. H. Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J. Biol. Chem. 258, 9302-9306 (1983).
85. Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T. & Ueda, N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279, 5298-5305 (2004).
86. Sugiura, T. et al. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 240, 53-62 (1996).
87. Cadas, H., di Tomaso, E. & Piomelli, D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17, 1226-1242 (1997).
88. Bisogno, T. et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163, 463-468 (2003).
89. Williams, E. J., Walsh, F. S. & Doherty, P. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J. Cell Biol. 160, 481-486 (2003).
90. Fernandez-Ruiz, J., Berrendero, F., Hernandez, M. L. & Ramos, J. A. The endogenous cannabinoid system and brain development. Trends Neurosci. 23, 14-20 (2000).
91. Lichtman, A. H., Shelton, C. C., Advani, T. & Cravatt, B. F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109, 319-327 (2004).
92. Clement, A. B., Hawkins, E. G., Lichtman, A. H. & Cravatt, B. F. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 23, 3916-3923 (2003).
93. Sipe, J. C., Chiang, K., Gerber, A. L., Bautler, E. & Cravatt, B. F. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl Acad. Sci. USA 99, 8394-8399 (2002).
94. Ligresti, A. et al. Further evidence for the specific process for the membrane transport of anandamide. Biochem. J. 380, 265-272 (2004).
95. Hillard, C. J., Edgemond, W. S., Jarrahian, A. & Campbell, W. B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69, 631-638 (1997).
96. Beltramo, M. et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097 (1997).
97. Bisogno, T., Maurelli, S., Melck, D., De Petrocellis, L. & Di Marzo, V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272, 3315-3323 (1997).
98. Bracey, M. H., Hanson, M. A., Masuda, K. R., Stevens, R. C. & Cravatt, B. F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298, 1793-1796 (2002).
99. Glaser, S. T. et al. Evidence against the presence of an anandamide transporter. Proc. Natl Acad. Sci. USA 100, 4269-4274 (2003).
100. Ortar, G., Ligresti, A., De Petrocellis, L., Morera, E. & Di Marzo, V. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol. 65, 1473-1481 (2003).
101. Lopez-Rodriguez, M. L. et al. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J. Med. Chem. 46, 1512-1522 (2003).
102. Fegley, D. et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl Acad. Sci. USA (in the press).
103. Hillard, C. J. & Jarrahian, A. Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol. 140, 802-808 (2003).
104. Cravatt, B. F. et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87 (1996).
105. Cravatt, B. F. et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl Acad. Sci. USA 98, 9371-9376 (2001).
106. Martin, B. R. et al. Cannabinoid properties of methylfluorophosphonate analogs. J. Pharmacol. Exp. Ther. 294, 1209-1218 (2000).
107. Kathuria, S. et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nature Med. 9, 76-81 (2003).
108. Leung, D., Hardouin, C., Boger, D. L. & Cravatt, B. F. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nature Biotechnol. 21, 687-691 (2003).
109. Karlsson, M., Contreras, J. A., Hellman, U., Tornqvist, H. & Holm, C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J. Biol. Chem. 272, 27218-27223 (1997).
110. Dinh, T. P. et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl Acad. Sci. USA 99, 10819-10824 (2002).
111. Ben-Shabat, S. et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353, 23-31 (1998).
112. 2, a peripheral cannabinoid receptor. Proc. Natl Acad. Sci. USA 96, 14228-14233 (1999).
113. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl Acad. Sci. USA 100, 10529-10533 (2003).
114. 2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627-634 (2002).
115. Rinaldi-Carmona, M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240-244 (1994).
116. Pinto, L. et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123, 227-234 (2002).
117. 1 receptors in the brainstem of the ferret. Gastroenterology 121, 767-774 (2001).
118. 1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198-203 (2001).
119. Cichewicz, D. L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 74, 1317-1324 (2004).
120. Naef, M. et al. The analgesic effect of oral Δ-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105, 79-88 (2003).
121. Di Marzo, V. et al. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur. J. Pharmacol. 406, 363-374 (2000).
122. 1 vanilloid receptor 'hybrid' ligands. Biochem. Biophys. Res. Commun. 281, 444-451 (2001).
123. 2 receptors. Eur. J. Pharmacol. 439, 83-92 (2002).
124. 1 cannabinoid receptors. Biochem. Biophys. Res. Commun. 262, 275-284 (1999).
125. 1 receptor affinity. Pharmacology 66, 89-99 (2002).
126. 2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 126, 665-672 (1999).
127. 2 receptor partial agonist with antihyperalgesic and anti-allodynic effects. J. Pharmacol. Exp. Ther. 310, 620-632 (2004).
128. Pertwee, R. G. in Cannabinoids (ed. Di Marzo, V.) 32-83 (Kluwer Academic, New York, 2004).
129. Wade, D. T., Robson, P., House, H., Makela, P. & Aram, J. A preliminary controlled study to determine whether wholeplant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17, 21-29 (2003).
130. Cannabis-based medicines - GW pharmaceuticals: high CBD, high THC, medicinal cannabis - GW pharmaceuticals, THC:CBD. Drugs RD 4, 306-309 (2003).
131. Pop, E. Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494-503 (2000).
132. Burstein, S. H. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr. Pharm. Des. 6, 1339-1345 (2000).
133. Sumariwalla, P. F. et al. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 50, 985-998 (2004).
134. Bisogno, T. et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845-852 (2001).
135. Feigenbaum, J. J. et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl Acad. Sci. USA 86, 9584-9587 (1989).
136. Liu, J., Li, H., Burstein, S. H., Zurier, R. B. & Chen, J. D. Activation and binding of peroxisome proliferator-activated receptor-γ by synthetic cannabinoid ajulemic acid. Mol. Pharmacol. 63, 983-992 (2003).
137. 1-antagonistic activity. WO0170700 (2001).
138. Makrijannis, A. & Deng, H. (Univ. Connecticut) Cannabimimetic indole derivatives. WO0128557 (2001).
139. Makrijannis, A. & Deng, H. (Univ. Connecticut) Retro-anandamides, high affinity and stability cannabinoid receptor ligands. WO0128498 (2001).
140. Mauler, F. et al. BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev. 9, 343-358 (2003).
141. 2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644-650 (1998).
142. 2 receptor. J. Pharmacol. Exp. Ther. 296, 420-425 (2001).
143. Pertwee, R. G. et al. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br. J. Pharmacol. 129, 1577-1584 (2000).
144. Zajicek, J. et al. UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362, 1517-1526 (2003).
145. Muller-Vahl, K. R. et al. Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J. Clin. Psychiatry 64, 459-465 (2003).
146. Sieradzan, K. A. et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57, 2108-2111 (2001).
147. Fox, S. H., Kellett, M., Moore, A. P., Crossman, A. R. & Brotchie, J. M. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov. Disord. 17, 145-149 (2002).
148. Porcella, A., Maxia, C., Gessa, G. L. & Pani, L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci. 13, 409-412 (2001).
149. Buggy, D. J. et al. Lack of analgesic efficacy of oral Δ-9-tetrahydrocannabinol in postoperative pain. Pain 106, 169-172 (2003).
150. Abrams, D. I. et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann. Intern. Med. 139, 258-266 (2003).
151. Grant, I., Gonzalez, R., Carey, C. L., Nataratan, L. & Wolfson, T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study, J. Int. Neuropsychol. Soc. 9, 679-689 (2003).
152. James, J. S. Marijuana safety study completed: weight gain, no safety problems. AIDS Treat. News 348, 3-4 (2000).
153. Tramer, M. R. et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323, 16-21 (2001).
154. Karst, M. et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290, 1757-1762 (2003).
155. Knoller, N. et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit. Care Med. 30, 548-554 (2002).
156. Di Marzo, V. et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264, 258-267 (1999).
157. Chevaleyre, V. & Castillo, P. E. Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38, 461-472 (2003).
158. 1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119, 481-496 (2003).
159. 1 receptor. Proc. Natl Acad. Sci. USA 98, 3662-3665 (2001).
160. 1 receptor. J. Pharmacol. Exp. Ther. 301, 1020-1024 (2002).
161. Huang, S. M. et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl Acad. Sci. USA 99, 8400-8405 (2002).
162. Martin, B. R., Mechoulam, R. & Razdan, R. K. Discovery and characterization of endogenous cannabinoids. Life Sci. 65, 573-595 (1999).
163. Bisogno, T. et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 248, 515-522 (1998).